BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007;56:1404-1409. [PMID: 17504943 DOI: 10.1136/gut.2006.114363] [Cited by in Crossref: 114] [Cited by in F6Publishing: 98] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 López-Martín C, Chaparro M, Espinosa L, Bejerano A, Maté J, Gisbert JP. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2011;34:385-392. [PMID: 21616565 DOI: 10.1016/j.gastrohep.2011.03.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
2 Mentzer A, Goel R, Elliott T, Campbell H, Hullah E, Patel P, Challacombe S, Escudier M, Sanderson JD. Azathioprine is effective for oral involvement in Crohn's disease but not for orofacial granulomatosis alone. J Oral Pathol Med 2016;45:312-8. [DOI: 10.1111/jop.12379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Meijer B, Simsek M, Blokzijl H, de Man RA, Coenraad MJ, Dijkstra G, van Nieuwkerk CM, Mulder CJ, de Boer NK. Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20-year cohort study in all Dutch liver transplant units. United European Gastroenterol J 2017;5:658-67. [PMID: 28815029 DOI: 10.1177/2050640616680550] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
4 van Asseldonk DP, Simsek M, de Boer NKH, Jharap B, Bloemena E, den Hartog G, Westerveld DB, Becx MC, Russel MG, Lissenberg-witte BI, van Nieuwkerk CM, Mulder CJJ, Verheij J, van Bodegraven AA. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients. Scandinavian Journal of Gastroenterology 2019;54:753-60. [DOI: 10.1080/00365521.2019.1629006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013;53:575-588. [PMID: 23408468 DOI: 10.1002/jcph.2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
6 Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009;7:80-85. [PMID: 18849016 DOI: 10.1016/j.cgh.2008.08.028] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 8.1] [Reference Citation Analysis]
7 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
8 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr Gastroenterol Rep 2009;11:509-17. [PMID: 19903428 DOI: 10.1007/s11894-009-0077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 de Boer NKH, Peyrin-biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel J, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis 2018;12:610-20. [DOI: 10.1093/ecco-jcc/jjx181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
11 Quezada SM, Mclean LP, Cross RK. Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology 2018;12:1183-91. [DOI: 10.1080/17474124.2018.1545574] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
12 Seinen ML, van Asseldonk DP, de Boer NK, Bouma G, van Nieuwkerk CM, Mulder CJ, Bloemena E, van Bodegraven AA. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol–Thiopurine Combination Therapy: . Inflammatory Bowel Diseases 2017;23:448-52. [DOI: 10.1097/mib.0000000000001036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
13 Piao C, Koul A, Gui D, Chen LX, Sarkar S. Noncirrhotic Portal Hypertension Secondary to Nodular Regenerative Hyperplasia Postrenal Transplant. ACG Case Rep J 2019;6:e00257. [PMID: 32042840 DOI: 10.14309/crj.0000000000000257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Marzano C, Cazals-Hatem D, Rautou PE, Valla DC. The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome. Hepatology. 2015;62:956-963. [PMID: 25684451 DOI: 10.1002/hep.27747] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
15 Seksik P, Mary J, Beaugerie L, Lémann M, Colombel J, Vernier-massouille G, Cosnes J. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine: . Inflammatory Bowel Diseases 2011;17:565-72. [DOI: 10.1002/ibd.21330] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
16 Luber RP, Honap S, Cunningham G, Irving PM. Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases? Front Med (Lausanne) 2019;6:279. [PMID: 31850357 DOI: 10.3389/fmed.2019.00279] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
17 Koller T, Galambosova M, Filakovska S, Kubincova M, Hlavaty T, Toth J, Krajcovicova A, Payer J. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol 2017; 23(22): 4102-4111 [PMID: 28652663 DOI: 10.3748/wjg.v23.i22.4102] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
18 Raj LS, Hawthorne AB. Optimising use of thiopurines in inflammatory bowel disease. Frontline Gastroenterol 2010;1:44-51. [PMID: 28839543 DOI: 10.1136/fg.2009.000174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
19 Seo JW, Kim ES, Han MH, Kweon YO. Non-cirrhotic portal hypertension related to azathioprine therapy in a patient with Crohn's disease. Intest Res 2021;19:247-51. [PMID: 32610890 DOI: 10.5217/ir.2020.00016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009;15:935-950. [PMID: 18985710 DOI: 10.1002/ibd.20797] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
21 Khoury T, Rmeileh AA, Yosha L, Benson AA, Daher S, Mizrahi M. Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. J Clin Transl Hepatol 2015;3:99-108. [PMID: 26356634 DOI: 10.14218/JCTH.2015.00007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
22 Restellini S, Chazouillères O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int 2017;37:475-89. [PMID: 27712010 DOI: 10.1111/liv.13265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
23 Simsek M, Meijer B, Ramsoekh D, Bouma G, van der Wouden EJ, den Hartog B, de Vries AC, Hoentjen F, Dijkstra G, de Boer SY, Jansen JM, van der Meulen AE, Beukers R, Brink MA, Steinhauser T, Oldenburg B, Gilissen LP, Naber TH, Verhagen MA, de Boer NKH, Mulder CJJ; Dutch Initiative on Crohn and Colitis (ICC). Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. Clin Gastroenterol Hepatol 2019;17:568-70. [PMID: 29775790 DOI: 10.1016/j.cgh.2018.05.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
24 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
25 Musumba CO. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther 2013;38:1025-37. [PMID: 24099468 DOI: 10.1111/apt.12490] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
26 Pola S, Boland BS, Lin GY, Kuo A, Sandborn WJ. Non-cirrhotic portal hypertension due to 6-mercaptopurine use for Crohn's disease. Dig Dis Sci 2014;59:1642-4. [PMID: 24535249 DOI: 10.1007/s10620-014-3052-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Ricart E, García-Bosch O, Ordás I, Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008; 14(36): 5523-5527 [PMID: 18810770 DOI: 10.3748/wjg.14.5523] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
28 Ortega-Alonso A, Andrade RJ. Chronic liver injury induced by drugs and toxins. J Dig Dis 2018;19:514-21. [PMID: 29808546 DOI: 10.1111/1751-2980.12612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
29 Meijer B, van Everdingen CK, Ramsoekh D, Stedman C, Frampton CMA, Mulder CJJ, Bouma G, de Boer NKH, Gearry RB. Transient elastography to assess liver stiffness in patients with inflammatory bowel disease. Dig Liver Dis 2018;50:48-53. [PMID: 29050997 DOI: 10.1016/j.dld.2017.09.128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
30 Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J. Further experience with the use of 6-thioguanine in patients with Crohn’s disease. Inflamm Bowel Dis. 2008;14:1399-1405. [PMID: 18521912 DOI: 10.1002/ibd.20492] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
31 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Capkin E, Karkucak M, Cosar AM, Ak E, Karaca A, Gokmen F, Budak BS, Tosun M. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study. Int J Rheum Dis 2015;18:548-52. [PMID: 24612551 DOI: 10.1111/1756-185X.12311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
33 Hernández-Gea V, Baiges A, Turon F, Garcia-Pagán JC. Idiopathic Portal Hypertension. Hepatology 2018;68:2413-23. [PMID: 30066417 DOI: 10.1002/hep.30132] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
34 Heimgartner B, Dawson H, De Gottardi A, Wiest R, Niess JH. Successful Treatment of Small Intestinal Bleeding in a Crohn's Patient with Noncirrhotic Portal Hypertension by Transjugular Portosystemic Shunt Placement and Infliximab Treatment. Case Rep Gastroenterol 2016;10:589-95. [PMID: 27920646 DOI: 10.1159/000450541] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Andrade RJ, Robles‐díaz M. Diagnostic and prognostic assessment of suspected drug‐induced liver injury in clinical practice. Liver Int 2019;40:6-17. [DOI: 10.1111/liv.14271] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
36 Bissonnette J, Généreux A, Côté J, Nguyen B, Perreault P, Bouchard L, Pomier-Layrargues G. Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension. J Gastroenterol Hepatol 2012;27:1336-40. [PMID: 22554152 DOI: 10.1111/j.1440-1746.2012.07168.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
37 Calabrese E, Hanauer SB. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease. J Crohns Colitis. 2011;5:48-53. [PMID: 21272804 DOI: 10.1016/j.crohns.2010.08.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
38 Nielsen OH, Coskun M, Steenholdt C, Rogler G. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2014;9:177-89. [DOI: 10.1586/17474124.2014.945914] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
39 Larrey D. Hépatotoxicité des immunosuppresseurs. Conduite diagnostique. Gastroentérologie Clinique et Biologique 2008;32:S194-204. [DOI: 10.1016/j.gcb.2008.04.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
40 Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: A review. World J Hepatol 2021; 13(12): 1956-1967 [DOI: 10.4254/wjh.v13.i12.1956] [Reference Citation Analysis]
41 Dridi I, Ben-cherif W, Aouam K, Haouas Z, Ben-attia M, Reinberg A, Boughattas NA. Circadian variation in hepatic toxicity of the immunosuppressive agent “Mycophenolate Mofetil” in rats. Biological Rhythm Research 2015;46:739-51. [DOI: 10.1080/09291016.2015.1052648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Dąbkowski K, Graca-pakulska K, Zawada I, Ostrowski J, Starzyńska T. Clinical significance of endoscopic findings in the upper gastrointestinal tract in Crohn’s disease. Scandinavian Journal of Gastroenterology 2019;54:1075-80. [DOI: 10.1080/00365521.2019.1656776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
43 Shanmugarajan T, Prithwish N, Somasundaram I, Arunsundar M, Niladri M, Lavande J, Ravichandiran V. Mitigation of Azathioprine-Induced Oxidative Hepatic Injury by the Flavonoid Quercetin in Wistar Rats. Toxicology Mechanisms and Methods 2008;18:653-60. [DOI: 10.1080/15376510802205791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
44 Schouten JNL, Nevens F, Hansen B, Laleman W, den Born M, Komuta M, Roskams T, Verheij J, Janssen HLA. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther 2012;35:1424-33. [DOI: 10.1111/j.1365-2036.2012.05112.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
45 Fousekis FS, Theopistos VI, Katsanos KH, Tsianos EV, Christodoulou DK. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Res. 2018;11:83-94. [PMID: 29707074 DOI: 10.14740/gr990w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
46 Al Maruf A, Wan L, O'Brien PJ. Evaluation of azathioprine-induced cytotoxicity in an in vitro rat hepatocyte system. Biomed Res Int 2014;2014:379748. [PMID: 25101277 DOI: 10.1155/2014/379748] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
47 Czaja AJ. Drug choices in autoimmune hepatitis: part B--Nonsteroids. Expert Rev Gastroenterol Hepatol. 2012;6:617-635. [PMID: 23061712 DOI: 10.1586/egh.12.38] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
48 Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, Francoz C, Denninger MH, Durand F, Bedossa P, Valla DC. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol. 2011;54:455-461. [PMID: 21087805 DOI: 10.1016/j.jhep.2010.07.038] [Cited by in Crossref: 85] [Cited by in F6Publishing: 69] [Article Influence: 7.1] [Reference Citation Analysis]
49 Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3-13. [PMID: 20374223 DOI: 10.1111/j.1365-2036.2010.04320.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 7.0] [Reference Citation Analysis]
50 Błogowski W, Marlicz W, Smereczyński A, Ławniczak M, Lewosiuk A, Starzyńska T. Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn’s disease. Immunopharmacology and Immunotoxicology 2010;33:398-402. [DOI: 10.3109/08923973.2010.509727] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
51 Hullah EA, Blaker PA, Marinaki AM, Escudier MP, Sanderson JD. A practical guide to the use of thiopurines in oral medicine. J Oral Pathol Med 2015;44:761-8. [PMID: 25529219 DOI: 10.1111/jop.12274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
52 Sun Y, Lan X, Shao C, Wang T, Yang Z. Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. J Gastroenterol Hepatol. 2019;34:1417-1423. [PMID: 30462857 DOI: 10.1111/jgh.14552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
53 de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:686-94. [DOI: 10.1038/ncpgasthep1000] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 5.6] [Reference Citation Analysis]
54 Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54:1071-1081. [PMID: 21574171 DOI: 10.1002/hep.24422] [Cited by in Crossref: 170] [Cited by in F6Publishing: 140] [Article Influence: 15.5] [Reference Citation Analysis]
55 Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr 2007;119:519-26. [DOI: 10.1007/s00508-007-0841-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
56 Ward MG, Patel KV, Kariyawasam VC, Goel R, Warner B, Elliott TR, Blaker PA, Irving PM, Marinaki AM, Sanderson JD. Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. United European Gastroenterol J 2017;5:563-70. [PMID: 28588888 DOI: 10.1177/2050640616663438] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
57 Bakshi N, Gulati N, Rastogi A, Chougule A, Bihari C, Jindal A. Nodular regenerative hyperplasia - An under-recognized vascular disorder of liver. Pathol Res Pract 2020;216:152833. [PMID: 32164988 DOI: 10.1016/j.prp.2020.152833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
58 Leal-valdivieso C, Naves JE, Mañosa M, Zabana Y, Cabré E, Domènech E. Hipertensión portal en pacientes con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2010;33:297-302. [DOI: 10.1016/j.gastrohep.2009.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Dinh MH, Stosor V, Rao SM, Miller FH, Green RM. Cryptogenic liver disease in HIV-seropositive men. HIV Med. 2009;10:447-453. [PMID: 19459992 DOI: 10.1111/j.1468-1293.2009.00712.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
60 European Association for the Study of the Liver;  Clinical Practice Guideline Panel: Chair;  Panel members;  EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70:1222-1261. [PMID: 30926241 DOI: 10.1016/j.jhep.2019.02.014] [Cited by in Crossref: 198] [Cited by in F6Publishing: 155] [Article Influence: 66.0] [Reference Citation Analysis]
61 Da BL, Koh C, Heller T. Noncirrhotic portal hypertension. Current Opinion in Gastroenterology 2018;34:140-5. [DOI: 10.1097/mog.0000000000000433] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Laharie D, Vergniol J, Bioulac-Sage P, Diris B, Poli J, Foucher J, Couzigou P, Drouillard J, de Lédinghen V. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010;22:487-93. [PMID: 19940782 DOI: 10.1097/MEG.0b013e328334098f] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
63 Tanji Y, Furukawa K, Igarashi Y, Yanagaki M, Haruki K, Shirai Y, Taniai T, Gocho T, Okui N, Ikegami T. Living donor liver transplantation for idiopathic portal hypertension with focal nodular hyperplasia. Surg Case Rep 2022;8:73. [PMID: 35445894 DOI: 10.1186/s40792-022-01428-3] [Reference Citation Analysis]
64 Vispo E, Moreno A, Maida I, Barreiro P, Cuevas A, Albertos S, Soriano V. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS. 2010;24:1171-1176. [PMID: 20299955 DOI: 10.1097/qad.0b013e3283389e26] [Cited by in Crossref: 68] [Cited by in F6Publishing: 16] [Article Influence: 6.2] [Reference Citation Analysis]
65 Selvarajah V, Montano-loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012;36:691-707. [DOI: 10.1111/apt.12042] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
66 Taylor KM, Ward MG, Blaker PA, Sparrow MP. Is there a role for thioguanine therapy in IBD in 2017 and beyond? Expert Review of Gastroenterology & Hepatology 2017;11:473-86. [DOI: 10.1080/17474124.2017.1294062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
67 Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn's disease. Digestive and Liver Disease 2008;40:709-16. [DOI: 10.1016/j.dld.2008.02.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
68 Toscano E, Cotta J, Robles M, Lucena MA, Andrade RJ. [Hepatotoxicity induced by new immunosuppressants]. Gastroenterol Hepatol. 2010;33:54-65. [PMID: 19889479 DOI: 10.1016/j.gastrohep.2009.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
69 Jharap B, van Asseldonk DP, de Boer NK, Bedossa P, Diebold J, Jonker AM, Leteurtre E, Verheij J, Wendum D, Wrba F. Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement. PLoS One. 2015;10:e0120299. [PMID: 26054009 DOI: 10.1371/journal.pone.0120299] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
70 van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011;43:270-276. [PMID: 20934926 DOI: 10.1016/j.dld.2010.09.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
71 Seo KI, Kang SB. [Hepatobiliary Manifestation of Inflammatory Bowel Disease]. Korean J Gastroenterol 2019;73:248-59. [PMID: 31132831 DOI: 10.4166/kjg.2019.73.5.248] [Reference Citation Analysis]
72 Miheller P, Lakatos PL. Thiopurines in Crohn’s disease, is there something new? Expert Opin Drug Metab Toxicol. 2010;6:1505-1514. [PMID: 20919963 DOI: 10.1517/17425255.2010.525505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
73 De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol. 2008;43:604-608. [PMID: 18415755 DOI: 10.1080/00365520701800266] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
74 López-Martín C, de la Fuente-Fernández E, Corbatón P, Sánchez MC, Gisbert JP. [Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease]. Gastroenterol Hepatol 2011;34:16-9. [PMID: 21168244 DOI: 10.1016/j.gastrohep.2010.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
75 Reuben A. Hepatotoxicity of Immunosuppressive Drugs. Drug-Induced Liver Disease. Elsevier; 2013. pp. 569-91. [DOI: 10.1016/b978-0-12-387817-5.00031-5] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
76 Schouten JN, Verheij J, Seijo S. Idiopathic non-cirrhotic portal hypertension: a review. Orphanet J Rare Dis. 2015;10:67. [PMID: 26025214 DOI: 10.1186/s13023-015-0288-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
77 Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013; 19(7): 1040-1048 [PMID: 23467510 DOI: 10.3748/wjg.v19.i7.1040] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
78 Chouchana L, Narjoz C, Beaune P, Loriot M, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease: Review: pharmacogenetics of thiopurines in IBD. Alimentary Pharmacology & Therapeutics 2012;35:15-36. [DOI: 10.1111/j.1365-2036.2011.04905.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 97] [Article Influence: 10.1] [Reference Citation Analysis]
79 Leung Y, Hanauer S. Conventional treatment in inflammatory bowel disease- recent trends. Immunosuppressants and biologic agents: should they or need they be used together? Gastroentérologie Clinique et Biologique 2009;33:S202-8. [DOI: 10.1016/s0399-8320(09)73155-0] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
80 Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. Journal of Crohn's and Colitis 2012;6:116-31. [DOI: 10.1016/j.crohns.2011.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
81 Belghiti J, Dokmak S, Vilgrain V, Paradis V. Benign liver lesions. Blumgart's Surgery of the Liver, Pancreas and Biliary Tract. Elsevier; 2012. pp. 1250-1267.e4. [DOI: 10.1016/b978-1-4377-1454-8.00079-5] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
82 Nicholls L, Montez J, Pelayo-Katsanis L, Katsanis E. Esophageal Varices in Adolescent and Young Adult Males with Acute Lymphocytic Leukemia. J Adolesc Young Adult Oncol 2019;8:217-20. [PMID: 30335538 DOI: 10.1089/jayao.2018.0098] [Reference Citation Analysis]
83 Morris JM, Oien KA, McMahon M, Forrest EH, Morris J, Stanley AJ, Campbell S. Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. Eur J Gastroenterol Hepatol. 2010;22:1001-1005. [PMID: 20075739 DOI: 10.1097/meg.0b013e3283360021] [Cited by in Crossref: 42] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
84 Kverka M, Rossmann P, Tlaskalova-Hogenova H, Klimesova K, Jharap B, de Boer NK, Vos RM, van Bodegraven AA, Lukas M, Mulder CJ. Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis. BMC Gastroenterol. 2011;11:47. [PMID: 21545711 DOI: 10.1186/1471-230x-11-47] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
85 Kummen M, Schrumpf E, Boberg KM. Liver abnormalities in bowel diseases. Best Pract Res Clin Gastroenterol. 2013;27:531-542. [PMID: 24090940 DOI: 10.1016/j.bpg.2013.06.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
86 Gonvers J, Juillerat P, Mottet C, Pittet V, Felley C, Vader J, Michetti P, Froehlich F. Maintenance of Medically Induced Remission of Crohn’s Disease. Digestion 2008;76:116-29. [DOI: 10.1159/000111026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
87 Zelinkova Z, Bultman E, Vogelaar L, Bouziane C, Kuipers EJ, van der Woude CJ. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J Gastroenterol 2012; 18(47): 6967-6973 [PMID: 23322995 DOI: 10.3748/wjg.v18.i47.6967] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
88 Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom. BMC Gastroenterol 2020;20:296. [PMID: 32917155 DOI: 10.1186/s12876-020-01441-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
89 Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337 [DOI: 10.4254/wjh.v14.i2.319] [Reference Citation Analysis]
90 Garg K, Kramer J, Eswaran S. Common Gastrointestinal Medications Implicated in Drug-Induced Liver Injury. Clin Liver Dis (Hoboken) 2021;18:184-8. [PMID: 34745575 DOI: 10.1002/cld.1110] [Reference Citation Analysis]
91 Shaked O, Siegelman ES, Olthoff K, Reddy KR. Biologic and Clinical Features of Benign Solid and Cystic Lesions of the Liver. Clinical Gastroenterology and Hepatology 2011;9:547-562.e4. [DOI: 10.1016/j.cgh.2011.03.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
92 Chevaux J, Peyrin-biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease: . Inflammatory Bowel Diseases 2011;17:1428-35. [DOI: 10.1002/ibd.21494] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
93 Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:157-165. [PMID: 20227029 DOI: 10.1016/j.bpg.2009.10.011] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 7.3] [Reference Citation Analysis]
94 Gentilucci UV, Gallo P, Perrone G, Vescovo RD, Galati G, Spataro S, Mazzarelli C, Pellicelli A, Afeltra A, Picardi A. Non-cirrhotic portal hypertension with large regenerative nodules: A diagnostic challenge. World J Gastroenterol 2011; 17(20): 2580-2584 [PMID: 21633664 DOI: 10.3748/wjg.v17.i20.2580] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
95 Larrey D, Meunier L, Valla D, Hillaire S, Hernandez-gea V, Dutheil D, Plessier A, Bureau C. Drug induced liver injury and vascular liver disease. Clinics and Research in Hepatology and Gastroenterology 2020;44:471-9. [DOI: 10.1016/j.clinre.2020.03.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Shamberg L, Vaziri H. Hepatotoxicity of Inflammatory Bowel Disease Medications. Journal of Clinical Gastroenterology 2018;52:674-84. [DOI: 10.1097/mcg.0000000000001084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
97 van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease. Inflamm Bowel Dis. 2016;22:2112-2120. [PMID: 27482972 DOI: 10.1097/mib.0000000000000869] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
98 Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis. 2009;3:162-167. [PMID: 21172265 DOI: 10.1016/j.crohns.2009.02.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
99 Dominique L. Liver toxicity of TNFalpha antagonists. Joint Bone Spine. 2008;75:636-638. [PMID: 18952478 DOI: 10.1016/j.jbspin.2008.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
100 Nahon S, Cadranel J, Chazouilleres O, Biour M, Jouannaud V, Marteau P. Liver and inflammatory bowel disease. Gastroentérologie Clinique et Biologique 2009;33:370-81. [DOI: 10.1016/j.gcb.2009.02.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
101 Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:479-484. [PMID: 20848520 DOI: 10.1002/ibd.21336] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
102 Vo HD, Xu J, Rabinowitz SS, Fisher SE, Schwarz SM. The Liver in Pediatric Gastrointestinal Disease. Journal of Pediatric Gastroenterology & Nutrition 2014;59:288-99. [DOI: 10.1097/mpg.0000000000000444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]